Shi Yongjie, Xiao Qiwen, Xiao Weichun, Kang Jiale, Zhou Qiang, Jia Hongyun, Chen Yimei, Huang Sicong
Department of Clinical Laboratory, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Sci Rep. 2025 Jul 29;15(1):27613. doi: 10.1038/s41598-025-09945-5.
Hepatocellular carcinoma (HCC) is frequently associated with Yeats-domain containing 2 (YEATS2) overexpression, which enhances tumor progression via the PI3K/AKT pathway. Our study delineates YEATS2's oncogenic functions in HCC and its potential as a prognostic and predictive biomarker. Through comprehensive in vitro and bioinformatics analyses, we reveal that YEATS2 promotes cell proliferation, invasion, and epithelial-mesenchymal transition (EMT). Additionally, YEATS2 modulates the tumor immune microenvironment and predicts response to immunotherapies and chemotherapies. YEATS2's serum stability suggests its utility as a non-invasive biomarker for personalized HCC treatment.
肝细胞癌（HCC）常与含Yeats结构域2（YEATS2）的过表达相关，后者通过PI3K/AKT途径促进肿瘤进展。我们的研究阐明了YEATS2在HCC中的致癌功能及其作为预后和预测生物标志物的潜力。通过全面的体外和生物信息学分析，我们发现YEATS2促进细胞增殖、侵袭和上皮-间质转化（EMT）。此外，YEATS2调节肿瘤免疫微环境，并预测对免疫疗法和化疗的反应。YEATS2在血清中的稳定性表明其可作为个性化HCC治疗的非侵入性生物标志物。
